NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics, Inc. (NMRA) for Potential Securities Fraud

NEW YORK CITY, NY / ACCESS Newswire / June 17, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc.") (NASDAQ:NMRA) concerning potential violations of the federal securities laws.

Neumora Therapeutics stock collapsed on June 15, 2026, after the company disclosed that navacaprant failed to meet primary and key secondary endpoints in both the Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder, and that the program would be discontinued immediately.

The same announcement disclosed an immediate workforce reduction of approximately 35%, signaling the scale of the financial impact. Prior to the collapse, NMRA traded at approximately $1.86 per share following years of capital raises and clinical spending directed primarily toward the navacaprant program. The dual-trial failure and simultaneous program termination eliminated the asset around which the company had built its near-term development strategy, as reflected in multiple quarterly earnings calls and SEC filings throughout 2025 and early 2026.

On the company's Q2 2025 earnings call on August 7, 2025, CFO Michael Milligan stated that the company anticipated cash runway "into 2027 well beyond all of our upcoming clinical milestones." The post-failure workforce reduction of roughly 35% raises questions about the assumptions underlying that projection.

If you suffered a loss on your Neumora Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212)363-7500

Fax: (212)363-7171

SOURCE: Levi & Korsinsky, LLP